Skip to main content

Table 3 Other medication use in the 6 months prior to and after tofacitinib initiation

From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

  Overall Biologic-naïve 1 prior biologic  ≥ 2 prior biologics
N = 225 N = 43 N = 92 N = 90
6-month baseline 6-month follow-up 6-month baseline 6-month follow-up 6-month baseline 6-month follow-up 6-month baseline 6-month follow-up
5-ASA, n (%) 112 (49.8) 70 (31.1) 25 (58.1) 16 (37.2) 49 (53.3) 30 (32.6) 38 (42.2) 24 (26.7)
Immunomodulator, n (%) 68 (30.2) 21 (9.3) 3 (7.0) 4 (9.3) 31 (33.7) 14 (15.2) 34 (37.8) 3 (3.3)
Oral corticosteroids, n (%)a 148 (65.8) 93 (41.3) 32 (74.4) 10 (23.3) 56 (60.9) 39 (42.4) 60 (66.7) 44 (48.9)
  Daily dose, mg/day, mean (SD)b 31.5 (16.2) 28.2 (13.5) 30.1 (18.2) 22.5 (17.9) 33.6 (19.7) 26.6 (14.1) 30.4 (10.6) 30.9 (11.3)
  1. Baseline was defined as the 6 months prior to index date. Follow-up period was 6 months following the index date
  2. 5-ASA, 5-aminosalicylates; n, number of patients in the specified category; N, number of patients in the treatment group; TNFi, tumour necrosis factor inhibitor
  3. aBased on pharmacy claims only
  4. bPrednisone equivalent